Genmab As Stock Market Value
| GNMSF Stock | USD 212.50 4.81 2.32% |
| Symbol | Genmab |
Genmab AS 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Genmab AS's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Genmab AS.
| 06/03/2024 |
| 11/30/2024 |
If you would invest 0.00 in Genmab AS on June 3, 2024 and sell it all today you would earn a total of 0.00 from holding Genmab AS or generate 0.0% return on investment in Genmab AS over 180 days. Genmab AS is related to or competes with Inhibikase Therapeutics, Purple Biotech, Synaptogenix, Legend Biotech, Blueprint Medicines, Ascendis Pharma, and Argenx NV. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark More
Genmab AS Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Genmab AS's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Genmab AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 13.03 | |||
| Value At Risk | (4.83) | |||
| Potential Upside | 3.34 |
Genmab AS Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Genmab AS's standard deviation. In reality, there are many statistical measures that can use Genmab AS historical prices to predict the future Genmab AS's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (1.30) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genmab AS's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Genmab AS Backtested Returns
Genmab AS holds Efficiency (Sharpe) Ratio of -0.12, which attests that the entity had a -0.12% return per unit of risk over the last 3 months. Genmab AS exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Genmab AS's Risk Adjusted Performance of (0.08), standard deviation of 2.89, and Market Risk Adjusted Performance of (1.29) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.26, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab AS's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab AS is expected to be smaller as well. At this point, Genmab AS has a negative expected return of -0.35%. Please make sure to check out Genmab AS's accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Genmab AS performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Genmab AS has no correlation between past and present. Overlapping area represents the amount of predictability between Genmab AS time series from 3rd of June 2024 to 1st of September 2024 and 1st of September 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Genmab AS price movement. The serial correlation of 0.0 indicates that just 0.0% of current Genmab AS price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 430.27 |
Genmab AS lagged returns against current returns
Autocorrelation, which is Genmab AS pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Genmab AS's pink sheet expected returns. We can calculate the autocorrelation of Genmab AS returns to help us make a trade decision. For example, suppose you find that Genmab AS has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Genmab AS regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Genmab AS pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Genmab AS pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Genmab AS pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Genmab AS Lagged Returns
When evaluating Genmab AS's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Genmab AS pink sheet have on its future price. Genmab AS autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Genmab AS autocorrelation shows the relationship between Genmab AS pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Genmab AS.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Correlation, Genmab AS Volatility and Genmab AS Alpha and Beta module to complement your research on Genmab AS. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Genmab AS technical pink sheet analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, pink sheet market cycles, or different charting patterns.